Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

Pain Clinical Trial

Official title:

The Use of Calcium and Magnesium for Prevention of Ixabepilone Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00998738
• Other study ID #: RC08CC
• Secondary ID: NCI-2009-01229RC
• Status: Terminated
• Phase: Phase 3
• First received: October 19, 2009
• Last updated: January 7, 2016
• Start date: November 2009
• Est. completion date: January 2013

Study information

• Verified date: November 2015
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This randomized phase III trial studies calcium and magnesium to see how well they work in preventing peripheral neuropathy caused by ixabepilone in patients with breast cancer. Giving calcium together with magnesium may stop or delay the development of peripheral neuropathy in patients with cancer who are receiving treatment with ixabepilone. It is not yet known whether calcium and magnesium are effective in preventing peripheral neuropathy caused by ixabepilone.

Description:

PRIMARY OBJECTIVES:

I. To compare ixabepilone-induced peripheral neuropathy (sensory) as measured by European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire (QLQ)-Chemotherapy-Induced Peripheral Neuropathy (CIPN)20 sensory subscale between calcium (Ca) Magnesium (Mg) and placebo arms.

SECONDARY OBJECTIVES:

I. To compare the incidence of CTCAE measured grade 2+ and/or grade 3+ peripheral neuropathy between CaMg and placebo arms.

II. To compare the times to onset of CTCAE measured grade 2+ and/or grade 3+ peripheral neuropathy between CaMg and placebo arms.

III. To compare the proportion of patients requiring ixabepilone dose reductions and/or stopping ixabepilone secondary to peripheral neuropathy (sensory) between CaMg and placebo arms.

IV. To assess the toxicity of CaMg in this situation. V. To document the incidence and severity of the acute pain syndrome (APS, commonly known as arthralgias/myalgias) induced by ixabepilone.

VI. To evaluate whether CaMg will decrease the acute pain syndrome (APS). VII. To evaluate the incidence and characteristics of, and change in, ixabepilone-APS over several cycles.

VIII. To evaluate the association between the ixabepilone-APS and eventual chemotherapy-induced neuropathy.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after each ixabepilone administration.

ARM II: Patients receive placebo IV over 30 minutes immediately before and after each ixabepilone administration.

After completion of study treatment, patients are followed up monthly for 12 months.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: January 2013
• Est. primary completion date: July 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Scheduled to undergo cancer treatment for metastatic breast cancer (weekly or once every three weeks) with ixabepilone with no prior exposure to ixabepilone and no more than 2 prior chemotherapy regimens for metastatic disease

• Serum calcium =< 1.2 x upper normal limit (UNL)

• Serum magnesium =< UNL

• Serum creatinine =< 1.5 x UNL

• Ability to sign informed consent and understand the nature of a placebo-controlled trial

• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2

• Ability to complete questionnaire(s) by themselves or with assistance

• Life expectancy >= 4 months

• Presence of a central line

Exclusion Criteria:

• Pre-existing history of peripheral neuropathy >= grade 2 (National Cancer Institute [NCI] CTCAE Active Version) due to any cause (chemotherapy, diabetes, alcohol, toxin, hereditary, etc.)

• Concurrent treatment with anticonvulsants, tricyclic antidepressants, or other neuropathic pain medications agents such as carbamazepine, phenytoin, valproic acid, gabapentin, lamotrigine, topical lidocaine patch, capsaicin cream, etc., or any other treatments specifically for prevention or treatment of neuropathy

• Other medical conditions, which in the opinion of the treating physician/allied health professional would make this protocol unreasonably hazardous for the patient

• Any of the following:

• Pregnant women

• Nursing women

• Women of childbearing potential (per physician judgment)

• Diagnosed diabetes requiring insulin or oral hypoglycemic medications

• Receiving digoxin or digitoxin

• History of heart block (any degree)

• Current treatment for arrhythmias

• Concurrent treatment with other neuropathic chemotherapy agents

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Breast Neoplasms
• Neuropathy
• Pain
• Peripheral Nervous System Diseases
• Recurrent Breast Carcinoma
• Stage IV Breast Cancer

Intervention

Drug:
• Calcium Gluconate
Given IV
• Magnesium Sulfate
Given IV

Other:
• Placebo
Given IV
• Quality-of-Life Assessment
Ancillary studies
• Questionnaire Administration
Ancillary studies

Drug:
• Ixabepilone
Given IV

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of Chemotherapy-induced Peripheral Neuropathy Between Calcium With Magnesium (CaMg) and Placebo Arms, as Measured by the Sensory Subscale of EORTC QLQ-CIPN20	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Module (EORTC QLQ-CIPN20) sensor subscale score was calculated following the standard scoring algorithm and was transformed to a 0 to 100 scale with 0=Low QOL and 100=Best QOL for data analysis.	During the first 18 weeks of ixabepilone-based therapy	No
Secondary	Percentage of Patients With Grade 2+ and/or Grade 3+ Neurotoxicity as Measured by NCI CTCAE Active Version Neuropathy Scale		Up to 12 months from initiation of ixabepilone	Yes
Secondary	Time to Onset of Grade 2+ and/or Grade 3+ Neurotoxicity as Assessed by NCI CTCAE Active Version	Time to onset of grade 2+ neurotoxicity was defined as time from randomization to the first occurrence of grade 2+ neurotoxicity. Time to onset of grade 3+ neurotoxicity was defined as time from randomization to the first occurrence of grade 3+ neurotoxicity.	Up to 12 months from initiation of ixabepilone	Yes
Secondary	Proportion of Patients Undergoing Dose Reduction or Discontinuing Ixabepilone Secondary to Peripheral Neuropathy		Up to 12 months from initiation of ixabepilone	No
Secondary	Average Cumulative Ixabepilone Dose		Up to 12 months from initiation of ixabepilone	No
Secondary	Toxicity Profile of CaMg Per CTCAE Active Version		Up to 12 months from initiation of ixabepilone	Yes
Secondary	Incidence of the Acute Pain Syndrome (APS)	APS was measured using the pain item which evaluated the aches/pains at its WORST in the last 24 hours in the scale of 0 to 10, with 0=no aches/pain and 10=aches/pains as bad as can be.; The outcome measures for each subsequent cycle will be analyzed in a similar fashion.	Treatment initiation to day 21 (Cycle 1)	No
Secondary	Severity of the Acute Pain Syndrome (APS)	APS was measured using the pain item which evaluated the aches/pains at its WORST in the last 24 hours in the scale of 0 to 10, with 0=no aches/pain and 10=aches/pains as bad as can be.; The outcome measures for each subsequent cycle will be analyzed in a similar fashion.	Treatment initiation to day 21 (Cycle 1)	No
Secondary	Association Between the Ixabepilone-APS and Eventual Chemotherapy-induced Neuropathy	Correlation coefficients will be produced relating the worst pain scores in the first cycle of therapy and the subsequent neuropathy scores as judged from the daily and weekly questions.	First cycle of therapy (up to 21 days)	No